VERTEX PHARMACEUTICALS INC / MA Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- VERTEX PHARMACEUTICALS INC / MA payments for repurchase of common stock for the quarter ending 2026-06-30 was $469.50M, a 19.83% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments for repurchase of common stock for the quarter ending 2026-03-31 was $336.90M, a 20.93% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments for repurchase of common stock for the quarter ending 2025-12-31 was $128.40M, a 69.27% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments for repurchase of common stock for the quarter ending 2025-09-30 was $1.07B, a 248.10% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments for repurchase of common stock for fiscal 2025 was $2.02B, a 71.39% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA payments for repurchase of common stock for fiscal 2024 was $1.18B, a 175.28% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA payments for repurchase of common stock for fiscal 2023 was $427.60M.
- VERTEX PHARMACEUTICALS INC / MA payments for repurchase of common stock for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $469.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $2.01B derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $336.90M 10-Q · filed 2026-05-05 | $1.93B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $128.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $2.02B 10-K · filed 2026-02-13 |
| 2025-09-30 | $1.07B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.31B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $391.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.54B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $426.10M 10-Q · filed 2026-05-05 | $1.47B derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $417.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $1.18B 10-K · filed 2026-02-13 |
| 2024-09-30 | $307.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $908.70M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $320.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $718.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $131.20M 10-Q · filed 2025-05-06 | $426.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $149.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $427.60M 10-K · filed 2026-02-13 |
| 2023-09-30 | $117.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $278.10M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $28.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $161.10M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $132.80M 10-Q · filed 2024-05-07 | $132.80M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $0.00 10-K · filed 2025-02-13 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $368.20M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $1.00B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-02 | $1.00B derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $368.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.43B 10-K · filed 2024-02-15 |
| 2021-09-30 | $632.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $1.19B derived: sum of 4 quarters · filed 2023-02-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $663.97M derived: sum of 4 quarters · filed 2023-02-10 |
| 2021-03-31 | $424.90M 10-Q · filed 2022-05-06 | $663.97M derived: sum of 4 quarters · filed 2023-02-10 |
| 2020-12-31 | $131.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $539.10M 10-K · filed 2023-02-10 |
| 2020-09-30 | $108.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $444.02M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $336.01M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-03-31 | $300.03M 10-Q · filed 2021-04-30 | $392.02M derived: sum of 4 quarters · filed 2022-02-09 |
| 2019-12-31 | $35.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $186.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $293.02M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $56.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $385.03M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $94.01M 10-Q · filed 2020-05-01 | $434.05M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $143.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $350.04M 10-K · filed 2021-02-11 |
| 2018-09-30 | $92.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $207.04M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $105.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $115.03M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $10.00M 10-Q · filed 2019-05-01 | $10.00M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $0.00 10-K · filed 2020-02-13 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-04-27 | |
| 2016-12-31 | $0.00 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |